Dr. Shambavi Richard welcomes viewers to Cancer Network's FACE-OFF, introducing a debate-driven educational program focused on the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM).
CAR-T vs BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma Navigating Treatment Selection, Sequencing, and the Evolving BCMA Treatment Landscape
Dr. Prashant Kapoor reviews the pivotal phase 1/2 LINKER-MM1 study evaluating linvoseltamab, a BCMA × CD3 bispecific antibody, in heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM).
Dr. Cesar Rodriguez presents findings from the phase 3 CARTITUDE-4 trial, which compared ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who were refractory to lenalidomide after one to three prior lines of therapy.
Following the presentation of the CARTITUDE-4 trial, the faculty discuss how the study findings may influence treatment strategies for relapsed/refractory multiple myeloma (R/R MM).
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
3
What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma
4
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
5